Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

The Effectiveness of Different Nebulized Solutions on Airway Clearance Function in Patients With Pneumonia

12. maj 2026 opdateret af: Chen, Yao-Hsiang
Pneumonia is a significant global and national health issue, particularly posing a notable threat to elderly population. Accumulation of sputum in pneumonia patients often results in impaired airway clearance, negatively impacting disease management and recovery. Clinically, nebulization therapy is widely employed to facilitate sputum clearance; however, evidence regarding the comparative effectiveness of different nebulized solution concentrations remains limited and inconsistent. Therefore, this study aims to evaluate and compare the clinical effects of nebulized solutions with various osmotic concentrations (3% hypertonic saline, 0.9% normal saline, 0.45% hypotonic saline, and distilled water) on airway clearance in patients with pneumonia. A randomized, double-blind controlled trial design will be used, recruiting 80 patients with pneumonia from a regional teaching hospital in northern Taiwan. Participants will be randomly assigned into four groups, receiving nebulized therapy four times daily over a period of seven days. This study outcome including the length of hospital stay, venous blood gas analysis, routine sputum examination, and arterial oxygen content. The findings of this the study are anticipated to provide evidence-based recommendations for the clinical application of nebulized solutions with different concentrations, aiming to enhance airway clearance efficiency, improve clinical care outcomes for pneumonia patients, and serve as a practical reference for healthcare professionals.

Studieoversigt

Status

Ikke rekrutterer endnu

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

80

Fase

  • Ikke anvendelig

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Diagnosed with pneumonia, defined by ICD-10 codes, including:

    J18: Pneumonia, unspecified organism J180: Bronchopneumonia, unspecified organism J181: Lobar pneumonia, unspecified organism J182: Hypostatic pneumonia, unspecified organism J188: Other pneumonia, unspecified organism J189: Pneumonia, unspecified organism

  2. Aged 18-100 years
  3. Clinical respiratory score > 3
  4. Patients unable to expectorate sputum spontaneously and requiring assisted suctioning

Exclusion Criteria:

  1. Diagnosis of influenza-associated pneumonia, defined by ICD-10 codes, including:

    J09X1: Influenza due to identified novel influenza A virus with pneumonia J1001: Influenza due to other identified influenza virus with the same identified influenza viral pneumonia J100: Influenza due to other identified influenza virus with pneumonia

  2. Diagnosis of COVID-19 infection, defined by ICD-10 code:

    U07.1: COVID-19, virus identified

  3. History of chronic obstructive pulmonary disease (COPD) (ICD-10 code: J44)
  4. History of lung cancer or metastatic cancer involving the lungs
  5. Current use of bronchodilators
  6. Patients requiring oral suctioning only
  7. Oxygen therapy with a flow rate > 10 L/min
  8. Clinical respiratory score > 8 (Table 2)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Kontrolgruppe
Comparison of different concentrations of saline solutions used for nebulization therapy
Aktiv komparator: Hypertonic group
Comparison of different concentrations of saline solutions used for nebulization therapy
Aktiv komparator: Isotonic group
Comparison of different concentrations of saline solutions used for nebulization therapy
Aktiv komparator: Hypotonic group
Comparison of different concentrations of saline solutions used for nebulization therapy

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Vein blood gas
Tidsramme: Measurements were performed before the intervention and at 7 days after the intervention.
Assessment of venous blood gas values including pH, pCO₂, and HCO₃-.
Measurements were performed before the intervention and at 7 days after the intervention.
Sputum routine examination
Tidsramme: Measurements were performed before the intervention and at 7 days after the intervention.
Assessment of sputum characteristics and routine laboratory findings.
Measurements were performed before the intervention and at 7 days after the intervention.
Arterial oxygen content (CaO₂)
Tidsramme: Measurements were performed before the intervention and at 7 days after the intervention.

Measurement of arterial oxygen content calculated from hemoglobin concentration, oxygen saturation, and partial pressure of oxygen.

Unit of Measure: mL O₂/dL blood

Measurements were performed before the intervention and at 7 days after the intervention.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Blood lactic acid level
Tidsramme: Measurements were performed before the intervention and at 7 days after the intervention.
Measurement of serum lactic acid concentration. Unit of Measure: mmol/L
Measurements were performed before the intervention and at 7 days after the intervention.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. maj 2026

Primær færdiggørelse (Anslået)

31. december 2027

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

27. april 2026

Først indsendt, der opfyldte QC-kriterier

12. maj 2026

Først opslået (Faktiske)

14. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

14. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. maj 2026

Sidst verificeret

1. april 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • TSGH-SS_D_115024

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Lungebetændelse

Kliniske forsøg med Nebulization therapy

Abonner